Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.255 -2.695 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.29 Bil PE Ratio: 0 PB Ratio: 1,065.02 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 03:00PM GMT
Release Date Price: $193.09 (+1.18%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good morning, everyone, and welcome to the 44th Goldman Sachs Conference. Really happy that everyone is here to join us.

Before we start, I'm just going to read a disclaimer. We are required to make certain disclosures in public appearances about Goldman Sachs' relationships with companies that we discuss. The disclosures relate to investment banking relationships, compensation received or 1% or more ownership. We are prepared to read aloud disclosures for any issuer during the sessions upon your request. However, these disclosures are available in our most recent reports available to you as clients in our firm portal. In addition, updates to these disclosures are available by ticker on the public website. Goldman Sachs agrees to host this conference on the basis that no third-party speaker will provide confidential or material nonpublic information. In addition, by attending the conference, you provide Goldman Sachs the right to record and redistribute the conference information. So these or third-party speakers do

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot